UW20038
OPEN TO ACCRUAL
PhII Trial of Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients with mCRC
UW23016
OPEN TO ACCRUAL
Phase II Liposomal Irinotecan w/ TAS102 & Bevacizumab for Patients w/ mCRC
UW23142
OPEN TO ACCRUAL
PII Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for Early Stage Anal Cancer
NRGGI004
OPEN TO ACCRUAL
Ph 3 mFOLFOX6/Bevacizumab/Atezolizumab vs. Atezolizumab in dMMR/MSI-H Metastatic Colorectal Cancer
NRGGI008
OPEN TO ACCRUAL
II/III Study of Colon Adjuvant Chemo Based on Eval of Residual Disease (CIRCULATE-NORTH AMERICA)
UW21061
OPEN TO ACCRUAL
Ph2 study of Pembrolizumab + Lenvatinib in Combo with Belzutifan in Solid Tumors
UW22112
OPEN TO ACCRUAL
PII of RO7198457 vs watchful waiting in ctDNA+, Resected Stage II (High Risk) & Stage III CRC
UW22129
OPEN TO ACCRUAL
Ph2 DKN-01 & FOLFIRI/FOLFOX + Bev vs. FOLFIRI/FOLFOX + Bev as 2L in adv. CRC
UW22123
OPEN TO ACCRUAL
PH1 Study of Intra-anally Administered Lopinavir/Ritonavir in Subjects with HIV with AIN 2/3